original ) (raw )The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
Samuel F Hunter
CNS drugs, 2015
View PDFchevron_right
Journal of Multiple Sclerosis The Effects of Fingolimod on T Cells and the Central Nervous System in the Pathogenesis of Multiple Sclerosis
Samuel F Hunter
View PDFchevron_right
Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients
Alessia Parodi
Journal of Neuroimmune Pharmacology, 2013
View PDFchevron_right
Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy
Hans-peter Hartung
Clinical Immunology, 2012
View PDFchevron_right
Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis
Tatsuro Misu , Ichiro Nakashima
Journal of Neuroimmunology, 2014
View PDFchevron_right
Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets
Nicolae Dandu
PLOS ONE, 2020
View PDFchevron_right
Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions
Ludwig Kappos
Current neurology and neuroscience reports, 2011
View PDFchevron_right
Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod
D. Matsuse , Jun-ichi Kira
PloS one, 2014
View PDFchevron_right
Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment
Karen Holdaway
Journal of Neuroimmunology
View PDFchevron_right
Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy
Toshiki Mizuno
Scientific reports, 2016
View PDFchevron_right
Fingolimod reduces the clinical expression of active demyelinating lesions in MS
Elisabetta Signoriello
Multiple Sclerosis and Related Disorders, 2018
View PDFchevron_right
Myeloid cells as target of fingolimod action in multiple sclerosis
Lucia Moiola
Neurology - Neuroimmunology Neuroinflammation, 2015
View PDFchevron_right
Fingolimod (FTY720): First approved oral therapy for multiple sclerosis
Sparsh Gupta
Journal of Pharmacology and Pharmacotherapeutics, 2011
View PDFchevron_right
Impaired T-cell migration to the CNS under fingolimod and dimethyl fumarate
Renaud Du Pasquier
Neurology - Neuroimmunology Neuroinflammation
View PDFchevron_right
Fingolimod: new oral treatment for relapsing-remitting MS
Klaus Schmierer
Prescriber, 2012
View PDFchevron_right
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
andreas billich
Nature Reviews Drug Discovery, 2010
View PDFchevron_right
Fingolimod Increases CD39-Expressing Regulatory T Cells in Multiple Sclerosis Patients
Christian Sindic
PLoS ONE, 2014
View PDFchevron_right
Effect of fingolimod on white blood cell, lymphocyte and neutrophil counts in MS patients
sara parsa
American journal of clinical and experimental immunology, 2019
View PDFchevron_right
Effect of Preventive and Curative Fingolimod Treatment Regimens on Microglia Activation and Disease Progression in a Rat Model of Multiple Sclerosis
David Vállez García
View PDFchevron_right
Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients
María Mansilla
CNS neuroscience & therapeutics, 2018
View PDFchevron_right
Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod
Claudio Gasperini
Therapeutics and clinical risk management, 2013
View PDFchevron_right
Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients
María Mansilla
CNS neuroscience & therapeutics, 2016
View PDFchevron_right
Japanese guidelines for fingolimod in multiple sclerosis: Putting into practice
Ichiro Nakashima
Clinical and Experimental Neuroimmunology, 2014
View PDFchevron_right
Fingolimod attenuates ceramide-induced blood–brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes
Ruben Van Doorn , Philip Nijland , Gijs Kooij
Acta Neuropathologica, 2012
View PDFchevron_right
Fingolimod modulates T cell phenotype and regulatory T cell plasticity in vivo
Khadir Raddassi
Journal of Autoimmunity
View PDFchevron_right
FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis
Felix Luessi , Helmut Jonuleit
Multiple Sclerosis Journal, 2015
View PDFchevron_right
Advances in the treatment of relapsing–remitting multiple sclerosis – critical appraisal of fingolimod
Claudio Gasperini
Therapeutics and Clinical Risk Management, 2013
View PDFchevron_right
Tumefactive MS lesions under fingolimod
Peter Wipfler
Neurology
View PDFchevron_right
Fingolimod alters intrathecal B cell maturation in multiple sclerosis patients
Jeffrey Bennett
2020
View PDFchevron_right
Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study
Judith Fraussen
PLoS ONE
View PDFchevron_right
Risk factors for fingolimod-induced lymphopenia in multiple sclerosis
Satoshi Kuwabara
Multiple sclerosis journal - experimental, translational and clinical
View PDFchevron_right
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approach
Claudio Gasperini
Drug Design, Development and Therapy, 2012
View PDFchevron_right
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients
Alessia Manni
Journal of Neuroimmunology, 2017
View PDFchevron_right
Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients
Ernst-Wilhelm Radue
Multiple sclerosis and related disorders, 2016
View PDFchevron_right
Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
Hans-peter Hartung
Neuropsychiatric Disease and Treatment, 2011
View PDFchevron_right